Literature DB >> 32002723

Prevalence of CNV-neutral structural genomic rearrangements in MLH1, MSH2, and PMS2 not detectable in routine NGS diagnostics.

Monika Morak1,2, Verena Steinke-Lange3,4, Trisari Massdorf3,4, Anna Benet-Pages3, Melanie Locher3, Andreas Laner3, Katrin Kayser5, Stefan Aretz5,6, Elke Holinski-Feder7,8.   

Abstract

Routine diagnostics for colorectal cancer patients suspected of having Lynch-Syndrome (LS) currently uses Next-Generation-Sequencing (NGS) of targeted regions within the DNA mismatch repair (MMR) genes. This analysis can reliably detect nucleotide alterations and copy-number variations (CNVs); however, CNV-neutral rearrangements comprising gene inversions or large intronic insertions remain undetected because their breakpoints are usually not covered. As several founder mutations exist for LS, we established PCR-based screening methods for five known rearrangements in MLH1, MSH2, or PMS2, and investigated their prevalence in 98 German patients with suspicion of LS without a causative germline variant or CNV detectable in the four MMR genes. We found no recurrence of CNV-neutral structural rearrangements previously described: Neither for two inversions in MLH1 (exon 1 and exon 16-19) within 33 MLH1-deficient patients, nor for two inversions in MSH2 (exon 1-7 and exon 2-6) within 48 MSH2-deficient patients. The PMS2 insertion in intron 7 was detected in one of 17 PMS2-deficient patients. None of the four genomic inversions constitutes a founder event within the German population, but we advise to test the rare cases with unsolved PMS2-deficiency upon the known insertion. As a next diagnostic step, tumour tissue of the unsolved patients should be sequenced for somatic variants, and germline analysis of additional genes with an overlapping clinical phenotype should be considered. Alternatively, full-length cDNA analyses may detect concealed MMR-defects in cases with family history.

Entities:  

Keywords:  Breakpoint screening; Founder mutations; Inversion; Lynch syndrome; NGS; Rearrangement

Year:  2020        PMID: 32002723     DOI: 10.1007/s10689-020-00159-4

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  35 in total

1.  Recurrence and variability of germline EPCAM deletions in Lynch syndrome.

Authors:  Roland P Kuiper; Lisenka E L M Vissers; Ramprasath Venkatachalam; Danielle Bodmer; Eveline Hoenselaar; Monique Goossens; Aline Haufe; Eveline Kamping; Renée C Niessen; Frans B L Hogervorst; Johan J P Gille; Bert Redeker; Carli M J Tops; Marielle E van Gijn; Ans M W van den Ouweland; Nils Rahner; Verena Steinke; Philip Kahl; Elke Holinski-Feder; Monika Morak; Matthias Kloor; Susanne Stemmler; Beate Betz; Pierre Hutter; David J Bunyan; Sapna Syngal; Julie O Culver; Tracy Graham; Tsun L Chan; Iris D Nagtegaal; J Han J M van Krieken; Hans K Schackert; Nicoline Hoogerbrugge; Ad Geurts van Kessel; Marjolijn J L Ligtenberg
Journal:  Hum Mutat       Date:  2011-03-01       Impact factor: 4.878

2.  Inversion of exons 1-7 of the MSH2 gene is a frequent cause of unexplained Lynch syndrome in one local population.

Authors:  Jennifer Rhees; Mildred Arnold; C Richard Boland
Journal:  Fam Cancer       Date:  2014-06       Impact factor: 2.375

3.  Biallelic MLH1 SNP cDNA expression or constitutional promoter methylation can hide genomic rearrangements causing Lynch syndrome.

Authors:  Monika Morak; Udo Koehler; Hans Konrad Schackert; Verena Steinke; Brigitte Royer-Pokora; Karsten Schulmann; Matthias Kloor; Wilhelm Höchter; Josef Weingart; Cortina Keiling; Trisari Massdorf; Elke Holinski-Feder
Journal:  J Med Genet       Date:  2011-06-28       Impact factor: 6.318

4.  Spectrum and frequencies of mutations in MSH2 and MLH1 identified in 1,721 German families suspected of hereditary nonpolyposis colorectal cancer.

Authors:  Elisabeth Mangold; Constanze Pagenstecher; Waltraut Friedl; Micaela Mathiak; Reinhard Buettner; Christoph Engel; Markus Loeffler; Elke Holinski-Feder; Yvonne Müller-Koch; Gisela Keller; Hans K Schackert; Stefan Krüger; Timm Goecke; Gabriela Moeslein; Matthias Kloor; Johannes Gebert; Erdmute Kunstmann; Karsten Schulmann; Josef Rüschoff; Peter Propping
Journal:  Int J Cancer       Date:  2005-09-20       Impact factor: 7.396

5.  Risk of colorectal and endometrial cancers in EPCAM deletion-positive Lynch syndrome: a cohort study.

Authors:  Marlies J E Kempers; Roland P Kuiper; Charlotte W Ockeloen; Pierre O Chappuis; Pierre Hutter; Nils Rahner; Hans K Schackert; Verena Steinke; Elke Holinski-Feder; Monika Morak; Matthias Kloor; Reinhard Büttner; Eugene T P Verwiel; J Han van Krieken; Iris D Nagtegaal; Monique Goossens; Rachel S van der Post; Renée C Niessen; Rolf H Sijmons; Irma Kluijt; Frans B L Hogervorst; Edward M Leter; Johan J P Gille; Cora M Aalfs; Egbert J W Redeker; Frederik J Hes; Carli M J Tops; Bernadette P M van Nesselrooij; Marielle E van Gijn; Encarna B Gómez García; Diana M Eccles; David J Bunyan; Sapna Syngal; Elena M Stoffel; Julie O Culver; Melanie R Palomares; Tracy Graham; Lea Velsher; Janos Papp; Edith Oláh; Tsun L Chan; Suet Y Leung; Ad Geurts van Kessel; Lambertus A L M Kiemeney; Nicoline Hoogerbrugge; Marjolijn J L Ligtenberg
Journal:  Lancet Oncol       Date:  2010-12-08       Impact factor: 41.316

6.  A 10-Mb paracentric inversion of chromosome arm 2p inactivates MSH2 and is responsible for hereditary nonpolyposis colorectal cancer in a North-American kindred.

Authors:  Anja Wagner; Heleen van der Klift; Patrick Franken; Juul Wijnen; Cor Breukel; Vladimir Bezrookove; Ron Smits; Yulia Kinarsky; Alicia Barrows; Barbara Franklin; Jane Lynch; Henry Lynch; Riccardo Fodde
Journal:  Genes Chromosomes Cancer       Date:  2002-09       Impact factor: 5.006

7.  BRAF mutation is frequently present in sporadic colorectal cancer with methylated hMLH1, but not in hereditary nonpolyposis colorectal cancer.

Authors:  Guoren Deng; Ian Bell; Suzanne Crawley; James Gum; Jonathan P Terdiman; Brian A Allen; Brindusa Truta; Marvin H Sleisenger; Young S Kim
Journal:  Clin Cancer Res       Date:  2004-01-01       Impact factor: 12.531

8.  Targeted deep-intronic sequencing in a cohort of unexplained cases of suspected Lynch syndrome.

Authors:  Dimitrij Frishman; Elke Holinski-Feder; Anke Marie Arnold; Monika Morak; Anna Benet-Pagès; Andreas Laner
Journal:  Eur J Hum Genet       Date:  2019-12-10       Impact factor: 4.246

9.  Haplotype analysis suggest that the MLH1 c.2059C > T mutation is a Swedish founder mutation.

Authors:  Jenny von Salomé; Tao Liu; Markku Keihäs; Moni Morak; Elke Holinski-Feder; Ian R Berry; Jukka S Moilanen; Stéphanie Baert-Desurmont; Annika Lindblom; Kristina Lagerstedt-Robinson
Journal:  Fam Cancer       Date:  2018-10       Impact factor: 2.375

10.  Next-generation sequencing approach for the diagnosis of human diseases: open challenges and new opportunities.

Authors:  Chiara Di Resta; Silvia Galbiati; Paola Carrera; Maurizio Ferrari
Journal:  EJIFCC       Date:  2018-04-30
View more
  4 in total

1.  Detecting inversions in routine molecular diagnosis in MMR genes.

Authors:  Edwige Kasper; Sophie Coutant; Sandrine Manase; Stéphanie Vasseur; Pierre Macquère; Gaëlle Bougeard; Laurence Faivre; Olivier Ingster; Stéphanie Baert-Desurmont; Claude Houdayer
Journal:  Fam Cancer       Date:  2022-01-08       Impact factor: 2.375

Review 2.  Should All Individuals Be Screened for Genetic Predisposition to Cancer?

Authors:  Sarah Wedderburn; Terri P McVeigh
Journal:  Genet Res (Camb)       Date:  2021-01-09       Impact factor: 1.588

Review 3.  Diagnosis of Lynch Syndrome and Strategies to Distinguish Lynch-Related Tumors from Sporadic MSI/dMMR Tumors.

Authors:  Julie Leclerc; Catherine Vermaut; Marie-Pierre Buisine
Journal:  Cancers (Basel)       Date:  2021-01-26       Impact factor: 6.639

4.  Genetic testing for inherited colorectal cancer and polyposis, 2021 revision: a technical standard of the American College of Medical Genetics and Genomics (ACMG).

Authors:  Rong Mao; Patti Krautscheid; Rondell P Graham; Arupa Ganguly; Suma Shankar; Matthew Ferber; Madhuri Hegde
Journal:  Genet Med       Date:  2021-06-17       Impact factor: 8.822

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.